News | August 09, 2023
Hikal posts Q1 FY 24 consolidated PAT at Rs. 6.92 Cr
US FDA approval is in line with de-risking strategy for additional API site to service our global customer base
US FDA approval is in line with de-risking strategy for additional API site to service our global customer base
The maker of ivermectin/pyrantel, the #1 vet-recommended and #1 dog-preferred real beef chew introduces the latest innovation in its portfolio
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
The company has extended its full co-operation and support to the officials of the Income Tax Department
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
The appointment is effective from May 01, 2023 for five years
The funds raised through the issue will be utilised to meet the working capital requirements to fund the company's expansion plans, entering new geographies and for general corporate purposes
The acquisition is for an enterprise value of Rs. 218 crores
This first joint plan on One Health aims to create a framework to integrate systems and capacity so that we can collectively better prevent, predict, detect, and respond to health threats
The company will address the observations within a stipulated timeline working with the regulators
Subscribe To Our Newsletter & Stay Updated
